Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Wes Stevens who wrote (25795)	1/9/2000 11:02:00 PM
From: johnsto1	Read Replies (2) \| Respond to of 56535

LJLB [LJLBioSystems] I think I found a good one here.The companies products help speed the process of biotech.Revenues up on sales and losses up because of hiring of sales people.It's not a sexy biotech but with a 2.7 float,26% institutionally held,at $8 it could become one.I'm buying Monday. 2 profiles: Capitalization % LT Debt to Total Cap 5% Owned by Institutions 26.2% Market Capitalization 100 Mil Avg Dly Vol (30 days) 31,600 Growth Rates Earnings $ % 5 Yr Hist Latest Qtr. (Sep 99) -.16 up 24% Latest 12 Months -.75 NA NA First Call Consensus Estimate LT Future Current Qtr. (Dec 99) -.16 up 16% Yr. Ended Dec. 99 -.72 up 13% 85% Yr. Ended Dec. 00 -.65 up 10% Revenues 5 Yr Hist Latest Qtr. (Sep 99) 2.6 Mil up 81% Latest 12 Months 7.6 Mil NA NA Dividends 5 Yr Hist Indicated Rate & Yield NA 0% Increases Last 5 Yrs NA NA Key Ratios & Measures 5 Yr. Range Current P/E NM NM Price to Book 2 - 22.5 18.4 Price to Cash Flow NA NM Price to Sales 3.1 - 17.2 13.15 Return on Equity NA NM Beta .99 Business Overview LJL BioSystems, Inc. designs and produces drug discovery products. The drug discovery process involves several stages including assay development, (reading and analyzing how drug compounds perform when tested against biological targets). LJL's proprietary technology platform addresses the throughput limitations of High Throughput Screening (HTS) systems. LJL's first HTS product, Analyst, is an assay detection instrument that performs up to 70,000 screens per day and offers the ability to read results in four different assay detection modes. LJL's Acquest product, offers state-of-the-art ultra HTS formats that increase the number of screens performed. Acquest can perform up to 200,000 tests per day. LJL markets its products through a direct sales force in North America and Europe. biz.yahoo.com

To: Wes Stevens who wrote (25795)	1/10/2000 6:52:00 PM
From: smchan	Read Replies (1) \| Respond to of 56535

My take on edig... Not sure what I think about these guys. I looked around their web page, and they seem to be focused on storage management for compact flash (CF) memory cards and digital recording (voice and music). I suppose these guys could be player for MP3 players and digital dictation devices; a market I don't really understand. MP3 - a format that is argueably worse than CD - seems to be a step in the wrong direction. After all, we have DVD over VHS, HDTV over NTSC, but MP3 over CD? But I digress. I understand the portability and the convenience. And I understand that pervasive devices are expected to rule in the near future. They will outnumber desktops by far. If those devices have voice and music functions, and if EDIG captures that market, they could be huge. But the only real alliances I see are with IBM and Lucent. Where's 3COM, HandSpring, and Microsoft (with WinCE)? (I leave out Intel b/c Intel is not yet a player in the pervasive market.) I sure do wish I'd bought some at 1/16 though. :-) Sam